Sort   by:  
 Page size 
ProteomicsMutation-specific and common phosphotyrosine signatures of KRAS G12D and G13D alleles
KRAS is one of the most frequently mutated genes across all cancer subtypes. Two of the most frequent oncogenic KRAS mutations observed in patients result in glycine to aspartic acid substitution at either codon 12 (G12D) or 13 (G13D). Although the biochemical differences between these two predomina...
ORGANISM(S): Homo sapiens (Human) 
2021-06-09 | PXD009843 | Pride
Sw48 Phosphoproteome G13d mutation G12d mutation Kras Signaling 
UnknownClinical significance of the KRAS G13D mutation in anastomotic recurrence of colorectal cancer.
Not available
S-EPMC10126653 | biostudies-literature
UnknownKRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
Not available
S-EPMC3930148 | biostudies-literature
UnknownStructural dataset for the fast-exchanging KRAS G13D.
Not available
S-EPMC4773362 | biostudies-literature
UnknownDiscernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
Not available
S-EPMC7643456 | biostudies-literature
ProteomicsA Systems Mechanism for KRAS Mutant Allele Specific Responses to Targeted Therapy
Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient’s tumor. For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KR...
ORGANISM(S): Homo sapiens (Human) 
2020-05-27 | PXD014755 | Pride
Thus resolving a problem in cancer personalized medicine. Systems approaches reveal why cancer patients with one specific kras mutation respond to egfr inhibitors 
UnknownDynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Not available
S-EPMC7222508 | biostudies-literature
UnknownCRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy.
Not available
S-EPMC9655013 | biostudies-literature
UnknownComparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras.
Not available
S-EPMC7191603 | biostudies-literature
ProteomicsKRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation
Oncogenic KRAS mutations are prevalent in colorectal cancer (CRC) and are associated with poor prognosis and resistance to therapy. There is a substantial diversity of KRAS mutant alleles observed in CRC. Emerging clinical and experimental analysis of common KRAS mutations suggest that each mutation...
ORGANISM(S): Mus musculus (Mouse) 
2025-05-02 | PXD050157 | Pride
Colorectal cancer Kras Acss2 
Sort   by:  
 Page size